for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GSK's long-acting HIV injection endorsed by EU panel

Oct 16 (Reuters) - GlaxoSmithKline Plc said on Friday an injection of its cabotegravir drug given every two months along with Johnson & Johnson’s rilpivirine was recommended for approval to treat HIV infections by a panel of the European health regulator.

The treatment is a long-acting regimen, which can reduce the number of doses required to 12 or six per year instead of a daily intake of pills. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Ramakrishnan M.)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up